Braidwell LP Buys New Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Braidwell LP purchased a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 34,094 shares of the company's stock, valued at approximately $654,000.

A number of other hedge funds also recently bought and sold shares of VRDN. FMR LLC raised its position in shares of Viridian Therapeutics by 6.2% during the 4th quarter. FMR LLC now owns 11,881,912 shares of the company's stock valued at $227,776,000 after buying an additional 698,434 shares in the last quarter. Vanguard Group Inc. raised its position in Viridian Therapeutics by 4.0% during the fourth quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company's stock valued at $88,087,000 after purchasing an additional 174,952 shares during the period. Alliancebernstein L.P. lifted its stake in shares of Viridian Therapeutics by 3.8% in the 4th quarter. Alliancebernstein L.P. now owns 2,286,994 shares of the company's stock valued at $43,842,000 after purchasing an additional 84,255 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Viridian Therapeutics by 38.6% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,670,000 shares of the company's stock worth $32,014,000 after purchasing an additional 465,000 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Viridian Therapeutics by 11.1% during the 4th quarter. Geode Capital Management LLC now owns 1,658,980 shares of the company's stock valued at $31,809,000 after purchasing an additional 165,669 shares during the last quarter.

Viridian Therapeutics Stock Down 1.9 %

NASDAQ VRDN traded down $0.24 during trading on Friday, reaching $12.54. 655,726 shares of the company's stock traded hands, compared to its average volume of 1,195,808. The company's 50 day simple moving average is $13.71 and its two-hundred day simple moving average is $17.53. Viridian Therapeutics, Inc. has a 12-month low of $9.90 and a 12-month high of $27.20. The firm has a market cap of $1.02 billion, a price-to-earnings ratio of -2.91 and a beta of 0.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $0.08. The company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.16 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm's revenue was up .0% on a year-over-year basis. As a group, sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on VRDN shares. HC Wainwright restated a "buy" rating and issued a $34.00 price target on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. JMP Securities dropped their price target on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research note on Wednesday. Needham & Company LLC cut their price target on shares of Viridian Therapeutics from $38.00 to $36.00 and set a "buy" rating on the stock in a report on Wednesday. Royal Bank of Canada dropped their target price on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a research report on Wednesday. Finally, The Goldman Sachs Group reduced their price target on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a report on Wednesday. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.18.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.